GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannapharmarx Inc (OTCPK:CPMD) » Definitions » Cash Flow from Operations

CPMD (Cannapharmarx) Cash Flow from Operations : $-1.75 Mil (TTM As of Mar. 2025)


View and export this data going back to 1999. Start your Free Trial

What is Cannapharmarx Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2025, Cannapharmarx's Net Income From Continuing Operations was $-0.69 Mil. Its Depreciation, Depletion and Amortization was $0.00 Mil. Its Change In Working Capital was $-0.41 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.48 Mil. Its Stock Based Compensation was $0.00 Mil. And its Cash Flow from Others was $0.02 Mil. In all, Cannapharmarx's Cash Flow from Operations for the three months ended in Mar. 2025 was $-0.60 Mil.


Cannapharmarx Cash Flow from Operations Historical Data

The historical data trend for Cannapharmarx's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannapharmarx Cash Flow from Operations Chart

Cannapharmarx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.56 -2.42 -1.45 -2.27 -1.70

Cannapharmarx Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -0.43 -0.54 -0.18 -0.60

Cannapharmarx Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Cannapharmarx's Cash Flow from Operations for the fiscal year that ended in Dec. 2024 is calculated as:

Cannapharmarx's Cash Flow from Operations for the quarter that ended in Mar. 2025 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannapharmarx  (OTCPK:CPMD) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Cannapharmarx's net income from continuing operations for the three months ended in Mar. 2025 was $-0.69 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Cannapharmarx's depreciation, depletion and amortization for the three months ended in Mar. 2025 was $0.00 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Cannapharmarx's change in working capital for the three months ended in Mar. 2025 was $-0.41 Mil. It means Cannapharmarx's working capital declined by $0.41 Mil from Dec. 2024 to Mar. 2025 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Cannapharmarx's cash flow from deferred tax for the three months ended in Mar. 2025 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Cannapharmarx's cash from discontinued operating Activities for the three months ended in Mar. 2025 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Cannapharmarx's asset impairment charge for the three months ended in Mar. 2025 was $0.48 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Cannapharmarx's stock based compensation for the three months ended in Mar. 2025 was $0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Cannapharmarx's cash flow from others for the three months ended in Mar. 2025 was $0.02 Mil.


Cannapharmarx Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Cannapharmarx's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannapharmarx Business Description

Traded in Other Exchanges
N/A
Address
3204-Rideau Place SW, Suite 302, Calgary, AB, CAN, T2S 1Z2
Cannapharmarx Inc specializes in the acquisition, development, and operation of cannabis cultivation facilities in Canada. The group evolved to focus on producing medical cannabis and craft products. Its products Unique Genetics, Craft Products, and Medical Cannabis.
Executives
Anthony Michael Panek director 95 SOUTH STATE STREET, SUITE 2300, SALT LAKE CITY UT 84111
Dominic Colvin director, officer: Chief Executive Officer C/O CANNAPHARMARX, INC., 2 PARK PLAZA, SUITE 1200-B, IRVINE CA 92614
John Hamilton Cassels officer: Chief Financial Officer SUITE 500, 209 8TH AVENUE SW, CALGARY A0 T2P 1B8
Richard Dale Orman director 302, 3204 RIDEAU PLACE SW, CALGARY A0 T2S1Z2
Andrew Clifford Steedman officer: Chief Operating Officer 1131 RIVERDALE AVE SW, CALGARY A0 T2S 0Y9
Marc R Branson director 977 KEITH ROAD, WEST VANCOUVER A1 V7T 1M6
Gary J Herick 10 percent owner 7609 RALSTON ROAD, ARVADA CO 80002
James F Samuelson director PO BOX 22, NEWPORT BEACH CA 92662
Matthew Nicosia director, 10 percent owner 2 PARK PLAZA, SUITE 400, IRVINE CA 92614
Robert M Liess director 2602 W. SAM ALLEN RD., PLANT CITY FL 33565
Mathew D Sherwood director P.O. BOX 4375, DILLON CO 80435
James E Smeeding director 4029 GILBERT AVENUE, DALLAS TX 75219
Elie M Khalife director 9447 E. CROSS CREEK STREET, WICHITA KS 67206
Steven J Rule director C/O CANNAPHARMARX, INC., ONE COLLINS DRIVE, SUITE 100, CARNEYS POINT NJ 08069
Alexander R Giaquinto director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920